Vistagen Therapeutics, Inc. balance sheet VTGN

Annual Quarterly

As of Jun 30, 2026, Vistagen Therapeutics, Inc. had total assets of $35.7 million and total liabilities of $11.3 million. Total assets were down 48.2% from a year earlier. Stockholders' equity was $24.5 million. It held $31.7 million in cash and investments against $783,000 of total debt, net cash of $30.9 million. The current ratio, current assets divided by current liabilities, was 3.07.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Q1 FY2027
Jun 30, 2026
Q4 FY2026
Mar 31, 2026
Q3 FY2026
Dec 31, 2025
Q2 FY2026
Sep 30, 2025
Q1 FY2026
Jun 30, 2025
Q4 FY2025
Mar 31, 2025
Q3 FY2025
Dec 31, 2024
Q2 FY2025
Sep 30, 2024
Assets
Cash
17
-65.3%
31
-54.1%
47
-36.6%
63
-25.5%
49
-52.4%
67
-43.7%
75
-41.0%
84
+124.0%
Short-term investments
15
+3.8%
15
+9.5%
14
+4.0%
14
+7.9%
14
+160.7%
13
14
13
Cash and investments
32
-49.8%
45
-43.6%
62
-30.3%
77
-20.9%
63
-41.7%
80
-32.5%
89
-30.0%
98
+159.5%
Total current assets
34
-48.6%
47
-42.8%
63
-29.7%
79
-21.0%
67
-39.8%
82
-32.0%
90
-29.8%
100
+155.8%
Property and equipment, net
0
-29.2%
0
-10.3%
0
+12.1%
1
+10.5%
1
+8.4%
0
+9.4%
0
-3.8%
0
+5.1%
Total assets
36
-48.2%
49
-42.4%
65
-29.5%
81
-21.0%
69
-39.3%
84
-31.8%
92
-29.6%
102
+142.9%
Liabilities and equity
Accounts payable
1
+105.8%
2
+135.1%
1
+23.2%
2
+156.1%
0
-59.8%
1
-57.8%
1
-40.2%
1
-45.2%
Total current liabilities
11
+0.3%
13
+1.5%
14
+40.6%
14
+81.4%
11
+78.9%
13
+146.2%
10
+131.0%
8
+158.6%
Total liabilities
11
-7.4%
13
-6.5%
14
+26.4%
15
+53.2%
12
+39.0%
14
+48.9%
11
+43.7%
10
+45.4%
Stockholders' equity
24
-56.9%
36
-49.5%
51
-37.2%
66
-28.6%
57
-45.8%
70
-38.4%
81
-34.2%
93
+160.8%
Debt
Lease liabilities
1
-45.0%
1
-37.2%
1
-38.8%
1
-32.7%
1
-28.5%
2
-28.8%
2
-24.0%
2
-24.6%
Total debt
1
-45.0%
1
-37.2%
1
-38.8%
1
-32.7%
1
-28.5%
2
-28.8%
2
-24.0%
2
-24.6%
Net cash
31
-49.9%
44
-43.7%
61
-30.1%
76
-20.7%
62
-41.9%
79
-32.5%
87
-30.1%
96
+171.9%
Ratios
Current ratio
3.07x
3.67x
4.67x
5.79x
5.98x
6.51x
9.35x
13.29x
Debt to equity
0.03x
0.03x
0.02x
0.02x
0.03x
0.02x
0.02x
0.02x
Return on equity
-276.21%
-196.19%
-131.67%
-93.82%
-98.26%
-73.05%
-58.31%
-42.55%
Return on assets
-189.22%
-143.49%
-103.06%
-76.90%
-80.93%
-60.96%
-51.25%
-38.60%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
VTGN (Nasdaq)
Fiscal year ends
March 31
Incorporated in
NV
Headquarters
South San Francisco, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1411685
Former names
Excaliber Enterprises, Ltd. (until Jun 8, 2011)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.